Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2024 Earnings Call Transcript November 7, 2024Iovance Biotherapeutics, Inc. beats earnings expectations.
Iovance Biotherapeutics Inc. (IOVA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 26,617,709 | $249,940,287 | +3% | 5.28% |
| 2. | MHR Fund Management Mark Rachesky | 23,997,103 | $225,332,797 | 24.57% | |
| 3. | Soleus Capital Guy Levy | 8,528,500 | $80,082,615 | +13% | 6.2% |
| 4. | Balyasny Asset Management Dmitry Balyasny | 4,472,576 | $41,997,489 | -2% | 0.06% |
| 5. | VenBio Select Advisor Kurt Von Emster | 4,240,000 | $39,813,600 | -64% | 0.58% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.15 | 250,000 | Director | 320,150 | 2024-02-20 | Filing | |
| $9.15 | 32,000 | Director | 54,000 | 2024-02-20 | Filing | |
| $9.15 | 5,000,000 | Director | 28,067,333 | 2024-02-20 | Filing | |
| $5.56 | 10,000 | Director | 248,633 | 2023-09-18 | Filing | |
| $5.30 | 5,000,000 | Director | 23,067,333 | 2023-09-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 50,000 | Director | 7,500 | 2024-11-12 | Filing | |
| $8.71 | 20,500 | Director | 100,000 | 2016-08-25 | Filing | |
| $9.10 | 33,500 | Director | 120,500 | 2016-08-24 | Filing | |
| $9.11 | 54,000 | Director | 100,000 | 2016-08-22 | Filing | |
| $7.13 | 16,500 | Director | 154,000 | 2015-09-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,812,820 | $185,468,227 | 0% | |
| 2. | 19,071,756 | $155,053,376 | 0% | |
| 3. | 16,424,388 | $133,530,274 | 0% | |
| 4. | 5,263,309 | $42,790,702 | 0.04% | |
| 5. | 5,037,098 | $40,956,054 | 0% |
News See All
8 Most Promising Stocks to Buy According to Wall Street Analysts
With only a few days left until the 2024 presidential election, investors are preparing for potential volatility to shake the stock market.
10 Best Biotech Stocks To Buy Under $20
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, technological advancements, and government support.
10 Stocks Under $10 With High Potential
There has been ongoing geopolitical in the Middle East, which escalated recently when Iran launched a series of missiles toward Israel.
10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2024 Earnings Call Transcript August 8, 2024Iovance Biotherapeutics, Inc. beats earnings expectations.
Here’s Why Iovance Biotherapeutics (IOVA) Declined in Q2
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Most Shorted Stocks That Are Loved by Analysts
Short selling is one of the more controversial ways of making money on the stock market.
Iovance Biotherapeutics (IOVA) Shares Rallied after the FDA approval of AMTAGVI™
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript
Operator: Welcome to the Iovance Biotherapeutics Conference Call to discuss the First Quarter 2024 Results and recent Corporate Updates. My name is Livia, and I'll be your operator for today's call.
Billionaire Hedge Funds
